Mohammed Z. Farooqui, Phd

Executive Director
Merck & Co., Inc.

Poster(s):

• 1509 - Nemtabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Cohort J of the Phase 2 BELLWAVE-003 Study

• 1510 - BELLWAVE-010: An Open-Label, Phase 3 Study of Nemtabrutinib Plus Venetoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

• 1511 - Nemtabrutinib in Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Phase 3 BELLWAVE-011 Study